{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:17:56Z","timestamp":1783696676957,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.medj.2026.101189","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:55:21Z","timestamp":1782744921000},"page":"101189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advanced cholangiocarcinoma in 2025: Therapeutic sequencing and global implementation"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9639-4486","authenticated-orcid":false,"given":"Fausto","family":"Petrelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Pesenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvia Milena","family":"Cribi\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Arru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Viti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Celotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Tomasello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ghidini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Zaniboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Baiocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ornella","family":"Garrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Ghidini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2026.101189_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","article-title":"Clinical practice guidelines on the management of intrahepatic cholangiocarcinoma","volume":"79","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.medj.2026.101189_bib2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2026.101189_bib3","first-page":"1655","article-title":"Cholangiocarcinoma","volume":"402","author":"Razumilava","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2026.101189_bib4","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine vs gemcitabine for biliary-tract cancer (ABC-02)","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101189_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cgh.2012.09.009","article-title":"Classification, diagnosis, and management of cholangiocarcinoma","volume":"11","author":"Razumilava","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.medj.2026.101189_bib6","doi-asserted-by":"crossref","first-page":"5613","DOI":"10.3390\/ijms22115613","article-title":"Molecular Landscape and Therapeutic Strategies in Cholangiocarcinoma: An Integrated Translational Approach towards Precision Medicine","volume":"22","author":"Casadio","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.medj.2026.101189_bib7","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/14737159.2025.2518145","article-title":"Best practices in sample management and molecular profiling of cholangiocarcinoma: a practical guide","volume":"25","author":"Castet","year":"2025","journal-title":"Expert Rev. Mol. Diagn."},{"key":"10.1016\/j.medj.2026.101189_bib8","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.idc.2010.07.006","article-title":"Cholangiocarcinoma: new insights into disease pathogenesis and biology","volume":"24","author":"Braconi","year":"2010","journal-title":"Infect. Dis. Clin. North Am."},{"key":"10.1016\/j.medj.2026.101189_bib9","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/jjco\/hyv213","article-title":"Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group. Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT)","volume":"46","author":"Mizusawa","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.medj.2026.101189_bib10","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","article-title":"Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial","volume":"30","author":"Morizane","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.medj.2026.101189_bib11","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","article-title":"Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial","volume":"5","author":"Shroff","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.medj.2026.101189_bib12","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jhep.2025.05.003","article-title":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","volume":"83","author":"Oh","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.medj.2026.101189_bib13","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin for advanced biliary tract cancer (KEYNOTE-966): a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2026.101189_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001240","article-title":"Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial","volume":"8","author":"Chen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.medj.2026.101189_bib15","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX vs active symptom control in advanced biliary cancer (ABC-06)","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medj.2026.101189_bib16","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.medj.2026.101189_bib17","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1200\/JCO.23.02010","article-title":"Trastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase II trial","volume":"42","author":"Ohba","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medj.2026.101189_bib18","doi-asserted-by":"crossref","unstructured":"Ahmad O., Rath S., Banatwala U.E.S.S., Alam U., Islam M.R., Wahid A., Sajjad F., Khan W.F., Gain A.M. Clinical Outcomes and Safety Profile of Adagrasib in KRAS G12C-Mutated Solid Tumors: A Single-Arm Meta-Analysis. Am J Clin Oncol. 2026;49:147-155. doi: 10.1097\/COC.0000000000001249.","DOI":"10.1097\/COC.0000000000001249"},{"key":"10.1016\/j.medj.2026.101189_bib19","unstructured":"ClinicalTrials.gov. (2025). MASTER-KEY umbrella trial for biliary tract cancers.NCT04267880 )."},{"key":"10.1016\/j.medj.2026.101189_bib20","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, FGFR2 fusion-positive cholangiocarcinoma (FIGHT-202)","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medj.2026.101189_bib21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medj.2026.101189_bib22","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant advanced cholangiocarcinoma (ClarIDHy)","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medj.2026.101189_bib23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s43018-024-00894-y","article-title":"Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial","volume":"6","author":"Marabelle","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.medj.2026.101189_bib24","doi-asserted-by":"crossref","first-page":"555","DOI":"10.5582\/bst.2024.01376","article-title":"First-line systemic therapy and sequencing options in advanced biliary tract cancer: A systematic review and network meta-analysis","volume":"18","author":"Xu","year":"2025","journal-title":"Biosci Trends"},{"key":"10.1016\/j.medj.2026.101189_bib25","article-title":"Inhibitors in Cholangiocarcinoma: A Real-World Experience at a Tertiary Center","volume":"6","author":"Rizzo","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.medj.2026.101189_bib26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2022.09.004","article-title":"Rational development of combination therapies for biliary tract cancers","volume":"78","author":"Harding","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.medj.2026.101189_bib27","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2022.11.005","article-title":"Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma","volume":"78","author":"Merters","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.medj.2026.101189_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2022.11.006","article-title":"Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine?","volume":"179","author":"Roth","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.medj.2026.101189_bib29","unstructured":"National Comprehensive Cancer Network. (2025). NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. Version 2.2025."},{"key":"10.1016\/j.medj.2026.101189_bib30","doi-asserted-by":"crossref","first-page":"103647","DOI":"10.1016\/j.esmoop.2024.103647","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer","volume":"9","author":"Chen","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.medj.2026.101189_bib31","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/14737159.2025.2521538","article-title":"From barriers to solutions: an expert-based algorithm for cholangiocarcinoma and other biliary tract cancers testing in the Era of precision oncology","volume":"25","author":"Stenzinger","year":"2025","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.medj.2026.101189_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102649","article-title":"Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing","volume":"122","author":"Stenzinger","year":"2024","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.medj.2026.101189_bib33","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/hep.31410","article-title":"The tumor microenvironment in cholangiocarcinoma progression","volume":"73","author":"Fabris","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2026.101189_bib34","first-page":"11","article-title":"Tumor microenvironment and immunology of cholangiocarcinoma","volume":"8","author":"Cadamuro","year":"2022","journal-title":"Hepatoma Res."},{"key":"10.1016\/j.medj.2026.101189_bib35","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.3390\/curroncol30040319","article-title":"Cancer-associated fibroblasts and extracellular matrix: therapeutical strategies for modulating the cholangiocarcinoma microenvironment","volume":"30","author":"Minini","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.medj.2026.101189_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.70057","article-title":"Targeting the tumor microenvironment in cholangiocarcinoma to improve immune checkpoint blockade: potential strategies and translational pre-clinical models","volume":"14","author":"Jessel","year":"2025","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.medj.2026.101189_bib37","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/13543784.2021.1865308","article-title":"Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy","volume":"30","author":"Wang","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.medj.2026.101189_bib38","first-page":"30","article-title":"Cholangiocarcinoma tumor microenvironment highlighting fibrosis and matrix components","volume":"9","author":"Caligiuri","year":"2023","journal-title":"Hepatoma Res."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026001923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026001923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:04:06Z","timestamp":1783695846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634026001923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2666634026001923"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2026.101189","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advanced cholangiocarcinoma in 2025: Therapeutic sequencing and global implementation","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2026.101189","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101189"}}